A Phase 1 interventional study of Ramucirumab in Pediatric Solid Tumor, Refractory Tumor and Recurrent Tumor, sponsored by Eli Lilly and Company. Completed at 21 sites in United States. Open to participants aged 12 Months to 21 Years. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 29 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Part A-Non-CNS Solid Tumors) Escalating doses of 8 milligrams per kilogram (mg/kg) or 12 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle. (Part B-CNS Tumors) Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.
Drug: Ramucirumab
Administered IV
Also known as: LY3009806, IMC-1121B, Cyramza
Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab
A DLT is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0: 1. Any death not clearly due to the underlying disease or extraneous causes 2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity 3. Grade ≥4 neutropenia or thrombocytopenia \>7 days 4. Grade ≥3 thrombocytopenia with bleeding 5. Grade ≥3 nausea/vomiting or diarrhea\>72 hours with adequate antiemetic and other supportive care 6. Grade ≥3 fatigue ≥1 week 7. Grade ≥3 electrolyte abnormality that lasts\>72 hours, unless the Participant has clinical symptoms, in which case all Grade 3+electrolyte abnormality regardless of duration should count as a DLT. 8. Grade ≥3 prolongation of QT interval corrected using the Fridericia formula on 2 separate electrocardiogram readings approximately 5 min apart.
Time frame: Baseline to Study Completion (Up to 42 Months)
Population Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
Population Pharmacokinetics (PK): Minimum observed plasma concentration of Ramucirumab.
Time frame: Predose, Cycle 1 Day 1 (end of infusion (EOI), 1 hour after EOI) and Cycle 1 Day 43 (1 hour after EOI)
Number of Participants With Anti-Ramucirumab Antibodies
Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.
Time frame: Predose Cycle 1 Day 1 through Follow-Up (Up to 42 Months)
Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline to Date of Objective Disease Progression (Up to 42 Months)
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline to Date of Objective Disease Progression (Up to 42 Months)
Duration of Response (DOR)
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 42 Months)
Overall Survival
Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.
Time frame: Baseline to Date of Death from Any Cause (Up to 42 Months)
| Milestone | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) |
|---|---|---|---|
| Started | 8 | 15 | 6 |
| Received at least 1 dose of study drug | 8 | 15 | 6 |
| Completed | 6 | 10 | 6 |
| Not completed | 2 | 5 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
A DLT is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0: 1. Any death not clearly due to the underlying disease or extraneous causes 2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity 3. Grade ≥4 neutropenia or thrombocytopenia \>7 days 4. Grade ≥3 thrombocytopenia with bleeding 5. Grade ≥3 nausea/vomiting or diarrhea\>72 hours with adequate antiemetic and other supportive care 6. Grade ≥3 fatigue ≥1 week 7. Grade ≥3 electrolyte abnormality that lasts\>72 hours, unless the Participant has clinical symptoms, in which case all Grade 3+electrolyte abnormality regardless of duration should count as a DLT. 8. Grade ≥3 prolongation of QT interval corrected using the Fridericia formula on 2 separate electrocardiogram readings approximately 5 min apart.
| Participants | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) |
|---|---|---|
| Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab | 1 | 1 |
Population Pharmacokinetics (PK): Minimum observed plasma concentration of Ramucirumab.
| microgram per milliliter (µg/mL) | 8 mg/kg Ramucirumab | 12 mg/kg Ramucirumab |
|---|---|---|
| Cycle 1 Day 1 | 30.0 ± 32 | 48.3 ± 41 |
| Cycle 1 Day 43 | 53.6 ± 31 | 80.2 ± 44 |
Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.
| participants | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) |
|---|---|---|---|
| Number of Participants With Anti-Ramucirumab Antibodies | 0 | 0 | 0 |
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) |
|---|---|---|---|
| Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) | 0 (0.0 to 41.0) | 0 (0.0 to 23.2) | 0 (0.0 to 45.9) |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) |
|---|---|---|---|
| Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR) | 62.5 (29.0 to 96.3) | 40.0 (17.7 to 71.1) | 33.3 (4.3 to 77.7) |
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
No measurements were reported for this outcome.
Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.
| Months | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) |
|---|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over Baseline, up to 4 years 8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 8 mg/kg Ramucirumab (Part A) | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| 12 mg/kg Ramucirumab (Part A) | 0/15 (0%) | 7/15 (46.7%) | 15/15 (100%) |
| 12 mg/kg Ramucirumab (Part B) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/8 | 3/15 | 0/6 |
| Kidney infectionInfections and infestations | 0/8 | 0/15 | 1/6 |
| HeadacheNervous system disorders | 1/8 | 0/15 | 1/6 |
| SeizureNervous system disorders | 0/8 | 0/15 | 1/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/8 | 2/15 | 0/6 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/8 | 2/15 | 0/6 |
| HypertensionVascular disorders | 1/8 | 0/15 | 0/6 |
| HypotensionVascular disorders | 1/8 | 0/15 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/8 | 1/15 | 0/6 |
| InfectionInfections and infestations | 0/8 | 1/15 | 0/6 |
| Event | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) |
|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 1/8 | 12/15 | 2/6 |
| Lymphocyte count decreasedInvestigations | 4/8 | 2/15 | 4/6 |
| AnaemiaBlood and lymphatic system disorders | 2/8 | 9/15 | 2/6 |
| FatigueGeneral disorders | 1/8 | 8/15 | 1/6 |
| NauseaGastrointestinal disorders | 4/8 | 7/15 | 1/6 |
| Alanine aminotransferase increasedInvestigations | 1/8 | 6/15 | 3/6 |
| Haemoglobin increasedInvestigations | 1/8 | 1/15 | 3/6 |
| HypermagnesaemiaMetabolism and nutrition disorders | 0/8 | 4/15 | 3/6 |
| VomitingGastrointestinal disorders | 3/8 | 7/15 | 2/6 |
| Decreased appetiteMetabolism and nutrition disorders | 1/8 | 7/15 | 1/6 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) | Total |
|---|---|---|---|---|
| Mean | 15.8 ± 3.33 | 11.9 ± 5.59 | 9.7 ± 5.9 | 12.5 ± 5.4 |
| Sex: Female, Male(Participants) | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) | Total |
|---|---|---|---|---|
| Female | 4 | 6 | 2 | 12 |
| Male | 4 | 9 | 4 | 17 |
| Ethnicity (NIH/OMB)(Participants) | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 2 | 6 |
| Not Hispanic or Latino | 6 | 12 | 4 | 22 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 3 |
| White | 7 | 12 | 4 | 23 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
| Region of Enrollment(Participants) | 8 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part A) | 12 mg/kg Ramucirumab (Part B) | Total |
|---|---|---|---|---|
| United States | 8 | 15 | 6 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Jul 2019, 43 months.
Results were first posted in Aug 2021, 2 years 1 month after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 43 months is above that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab